The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing the 2019 novel coronavirus disease (COVID-19), was introduced by WHO (World Health Organization) as "pandemic" in March 2020. According to WHO, thus far (23 November 2020) 58,425,681 infected cases including 1,385,218 deaths have been reported worldwide. In order to reduce transmission and spread of this lethal virus, attempts are globally being made to develop an appropriate vaccine. Intending to neutralize pathogens at their initial entrance site, protective mucosal immunity is inevitably required. In SARS-CoV2 infection and transmission, respiratory mucosa plays a key role; hence, apparently mucosal vaccination could be a superior approach to elicit mucosal and systemic immune responses simultaneously. In this review,

SUBMITTER: Moradi-Kalbolandi S 

PROVIDER: S-EPMC7996120 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature